1. Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, R, Modigliani R, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn"s disease. Gastroenterology 2002; 122: 512 - 30.

2. F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn"s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017; 11(1): 3 - 25.

3. Peyrin-Biroulet L. Transmural healing as a therapeutic goal in Crohn"s disease: a systematic review. Lancet Gastroenterol Hepatol. 2021; 6(8): 659 - 667.

4. Министерство здравоохранения Российской Федерации. Клинические рекомендации "Ревматоидный артрит". Available: https://cr.minzdrav.gov.ru/schema/250_2.

5. de Souza HS, Fiocchi C. Immunopathogenesis of IBD: current state of the art. Nat Rev Gastroenterol Hepatol. 2016; 13(1): 13 - 27.

6. Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn"s disease. Gut. 2017; 66(5): 813 - 822.

7. Mak WY, Zhao M, Ng SC, et al. The epidemiology of inflammatory bowel disease: East meets West. Journal of Gastroenterology and Hepatology. 2020; 35: 380 - 389.

8. Burisch J., Jess T., Martinato M., Lakatos P. on behalf of ECCO-EpiCom. The burden of inflammatory bowel disease in Europe. JCC, 2013; 7: 322 - 337.

9. Ng SC, Shi HY, Hamidi N et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769 - 78.

10. Burisch J, Pedersen N, S, et al. East-West gradient in the incidence of inflammatory bowel disease in Europe: The ECCO-EpiCom inception cohort. Gut, 2014; 63(4): 588 - 97.

11. Князев О.В., Шкурко Т.В., Фадеева Н.А. и соавт. Эпидемиология хронических воспалительных заболеваний кишечника. Вчера, сегодня, завтра. Экспериментальная и клиническая гастроэнтерология. 2017; 3(139): 4 - 12.

12. Плотникова Е.Ю., Чашкова Е.Ю. Некоторые аспекты лечения воспалительных заболеваний кишечника. Лечащий врач. 2019; 8: 14 - 20.

13. Чашкова Е.Ю., Коротаева Н.С., Пак В.Е. и соавт. Клинико-эпидемиологические аспекты язвенного колита в Иркутской области. Колопроктология. 2023; 22(1): 108 - 116.

14. Белоусова Е.А., Шелыгин Ю.А., Ачкасов С.И. и соавт. Клинико-демографические характеристики и лечебные подходы у пациентов с воспалительными заболеваниями кишечника (болезнь Крона, язвенный колит) в РФ. Первые результаты анализа Национального регистра. Колопроктология. 2023; 22(1): 65 - 82. doi: 10.33878/2073-7556-2023-22-1-65-822023.

15. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19(Suppl A): 5 - 36.

16. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn"s disease. Inflamm Bowel Dis. 2002; 8: 244 - 50.

17. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn"s disease activity index. National Cooperative Crohn"s Disease Study. Gastroenterology. 1976; 70(3): 439 - 44.

18. Harvey RF, Bradshaw JM. A simple index of Crohn"s-disease activity. Lancet 1980; 315 (8167): 514.

19. Белоусова Е.А. Рекомендации по диагностике и лечению болезни Крона. Фарматека. 2009; 13: 38 - 44;

20. Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016,10(3): 239 - 254.

21. Vavricka SR, Schoepfer A, Scharl M, et al. Extraintestinal manifestations of inflammatory bowel disease. Inflam Bowel Dis. 2015; 21 (8): 1982 - 1992.

22. Egeberg A, Mallbris L, Warren RB, et al. Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. Br J Dermatol. 2016 Sep; 175(3): 487 - 92.

23. Белоусова Е.А., Халиф И.Л., Абдулганиева Д.И. и соавт. Социально-демографическая характеристика, особенности течения и варианты лечения воспалительных заболеваний кишечника в России. Результаты двух многоцентровых исследований. Альманах клинической медицины. 2018; 46(6): 445 - 463. doi: 10.18786/2072-0505-2018-46-6.

24. Lichtenstein GR, Loftus EV, Isaacs KL et al. ACG Clinical Guideline: Management of Crohn"s Disease in Adults. Am J Gastroenterol. 2018; 113(4): 481 - 517. doi: 10.1038/ajg.2018.27.

25. Чашкова Е.Ю., Владимирова А.А., Неустроев В.Г. и соавт. Воспалительные заболевания толстой кишки - аспекты диагностики. Бюллетень Восточно-Сибирского научного центра СО РАМН. 2011; 4-2: 209 - 221.

26. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989; 170: 2 - 6.

27. Daperno M, D"Haens G, Van Assche G et al. Development and validation of a new, simplified endoscopic activity score for Crohn"s disease: the SES-CD. Gastrointest Endosc. 2004; 60(4): 505 - 12. doi: 10.1016/s0016-5107(04)01878-4.

28. Тертычный А.С., Андреев А.И., Гебоэс К. Современные подходы к морфологической диагностике воспалительных заболеваний кишечника на материале эндоскопических биопсий. Архив патологии. 2011; 1(73): 40 - 47.

29. Шелыгин Ю.А., Благодарный Л.А. Справочник по колопроктологии. "Литтерра", 2012. 608 с.

30. Dignass AU, Gasche C, Bettenworth D, et al. European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases. J Crohns Colitis 2015; 9: 211 - 22.

31. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm.Bowel.Dis. 2004; 10: 661 - 665.

32. D"Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007; 22: 429 - 37.

33. Jensen M.D., Kjeldsen J., Nathan T. Fecal calprotectin is equally sensitive in Crohn"s disease affecting the small bowel and colon. Scand. J. Gastroenterol. 2011; 46: 694 - 700. doi: 10.3109/00365521.2011.560680.

34. Menees SB, Powell C, Kurlander J et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015; 110: 444 - 454.

35. Kennedy NA, Clark A, Walkden A et al. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16 - 50 years. J Crohns Colitis 2015; 9: 41 - 49.

36. Issa M, Vikayapal A, Gracham MB et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007; 5: 345 - 351.

37. Rodeman JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 339 - 344.

38. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1432 - 42.

39. Nguyen GC, Kaplan GG, Harris ML et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008; 103: 1443 - 50.

40. Сухина М.А., Юдин С.М., Загайнова А.В. и соавт. Практические рекомендации по лабораторной диагностике анаэробной инфекции. М.: "Триада", 2022, 84 с.

41. Kim JJ, Simpson N, Klipfel N. et al. Cytomegalovirus infection in patients with active inflammatory bowel disease. Dig Dis Sci. 2010 Apr; 55(4): 1059 - 65. doi: 10.1007/s10620-010-1126-4.

42. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004; 16: 775 - 8.

43. Nolan DJ. Radiology of inflammatory bowel disease. Br J Hosp Med. 1986; 36(2): 128 - 32.

44. Long B, Robertson J, Koyfman A. Emergency Medicine Evaluation and Management of Small Bowel Obstruction: Evidence-Based Recommendations. J Emerg Med. 2019; 56(2): 166 - 176. doi: 10.1016/j.jemermed.2018.10.024.

45. Coremans G, Rutgeerts P, Geboes K, et al. The value of ileoscopy with biopsy in the diagnosis of intestinal Crohn"s disease. Gastrointest Endosc 1984; 30: 167 - 72.

46. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53 Suppl 5: V1 - 16.

47. Marshall JK, Cawdron R, Zealley I, et al. Prospective comparison of small bowel meal with pneumocolon versus ileo-colonoscopy for the diagnosis of ileal Crohn"s disease. Am J Gastroenterol. 2004; 99: 1321 - 9.

48. Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013; 7(10): 827 - 51. doi: 10.1016/j.crohns.2013.06.001.

49. Khanna R, Zou G, Stitt L, et al. Responsiveness of Endoscopic Indices of Disease Activity for Crohn"s Disease. Am J Gastroenterol. 2017; 112(10): 1584 - 1592. doi: 10.1038/ajg.2016.580.

50. Cameron DJ. Upper and lower gastrointestinal endoscopy in children and adolescents with Crohn"s disease: a prospective study. J Gastroenterol Hepatol. 1991; 6(4): 355 - 8.

51. Thakkar K, Lucia CJ, Ferry GD, et al. Repeat endoscopy affects patient management in pediatric inflammatory bowel disease. Am J Gastroenterol. 2009; 104(3): 722 - 7. doi: 10.1038/ajg.2008.111.

52. Church PC, Kuint RC, Ledder O, et al. Magnetic Resonance Enterography Cannot Replace Upper Endoscopy in Pediatric Crohn Disease: An Imagekids Sub-study. J Pediatr Gastroenterol Nutr. 2018; 67(1): 53 - 58. doi: 10.1097/MPG.0000000000001869.

53. Horsthuis K, Bipat S, Bennink RJ, Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: metaanalysis of prospective studies. Radiology 2008; 247(1): 64 - 79.

54. Bettenworth D, Bokemeyer A, Baker M, et al. Assessment of Crohn"s disease-associated small bowel strictures and fibrosis on cross-sectional imaging: a systematic review. Gut. 2019; 68(6): 1115 - 1126. doi: 10.1136/gutjnl-2018-318081.

55. Chidi VN, Schwartz DA. Imaging of perianal fistulizing Crohn"s disease. Expert Rev Gastroenterol Hepatol. 2015; 9(6): 797 - 806. doi: 10.1586/17474124.2015.1031110.

56. Sheedy SP, Bruining DH, Dozois EJ, et al. MR Imaging of Perianal Crohn Disease. Radiology. 2017; 282(3): 628 - 645. doi: 10.1148/radiol.2016151491.

57. Zawadzki A, Starck M, Bohe M, et al. A unique 3D endoanal ultrasound feature of perianal Crohn"s fistula: the "Crohn ultrasound fistula sign". Colorectal Dis. 2012; 14(9): 608 - 11. DOI: 10.1111/j.1463-1318.2012.03047.

58. Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn"s disease. Gut. 2014; 63: 1381 - 1392. DOI: 10.1136/gutjnl-2013-306709.

59. Alabiso ME, Iasiello F, Pellino G, et al. 3D-EAUS and MRI in the Activity of Anal Fistulas in Crohn"s Disease. Gastroenterol Res Pract. 2016; 2016: 1895694. DOI: 10.1155/2016/1895694.

60. Tandon P, James P, Cordeiro E, et al. Diagnostic Accuracy of Blood-Based Tests and Histopathology for Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2017; 23(4): 551 - 560. doi: 10.1097/MIB.0000000000001073.

61. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68 (Suppl 3): 1 - 106. doi: 10.1136/gutjnl-2019-318484.

62. Fraquelli M, Colli A, Casazza G, et al. Role of US in detection of Crohn disease: meta-analysis. Radiology. 2005; 236: 95 - 101.

63. Martinez MJ, Ripolles T, Paredes JM, et al. Assessment of the extension and the inflammatory activity in Crohn"s disease: comparison of ultrasound and MRI. Abdom Imaging 2009; 34: 141 - 8.

64. Panes J, Bouzas R, Chaparro M, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn"s disease. Aliment Pharmacol Ther. 2011; 34: 125 - 45.

65. Воробьев Г.И., Орлова Л.П., Самсонова Т.В., и соавт. Возможности ультразвукового исследования в диагностике болезни Крона. Ультразвуковая и функциональная диагностика. 2010; 1: 29 - 36.

66. Самсонова Т.В., Орлова Л.П. Ультразвуковая семиотика болезни Крона тонкой кишки. Колопроктология. 2014; 1(47): 60 - 68.

67. Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn"s disease: a meta-analysis. Am J Gastroenterol. 2010; 105(6): 1240 - 8. doi: 10.1038/ajg.2009.713.

68. Spada C, Riccioni ME, Costamagna G. Patients with known small bowel stricture or with symptoms of small bowel obstruction secondary to Crohn's disease should not perform video capsule endoscopy without previously tested for small bowel patency. Am J Gastroenterol. 2007; 102: 1542 - 3.

69. Spada C, Shah SK, Riccioni ME et al. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J Clin Gastroenterol. 2007; 42: 576 - 82.

70. Schulz C, K, Salheiser M, et al. Double-balloon enteroscopy in the diagnosis of suspected isolated Crohn"s disease of the small bowel. Dig Endosc. 2014; 26(2): 236 - 42. doi: 10.1111/den.12142.

71. Tontini GE, Vecchi M, Pastorelli L, et al. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. World J Gastroenterol. 2015; 21(1): 21 - 46.

72. IBD Mimics: Most Common Conditions Misdiagnosed as IBD. https://www.crohnscolitisfoundation.org/ClinicalPearls2020.

73. Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol 2018; 3(9): 644 - 653. doi: 10.1016/S2468-1253(18)30159-6.

74. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn"s disease: Current management. J Crohns Colitis. 2010; 4(1): 28 - 62.

75. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol.2015; 110(9): 1324 - 1338. https://doi.org/10.1038/ajg.2015.233.

76. Turner D, Ricciuto A, Lewis A. et al. International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021; 160(5): 1570 - 1583. doi: 10.1053/j.gastro.2020.12.031.

77. Халиф И.Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006; 3(16): 58 - 62.

78. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018; 390(10114): 2779 - 2789. doi: 10.1016/S0140-6736(17)32641-7.

79. F, Dignass A, Annese V, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn"s Disease 2016: Part 1: Diagnosis and Medical Management. J Crohns Colitis. 2017; 11(1): 3 - 25. doi: 10.1093/ecco-jcc/jjw168.

80. Абдулганиева Д.И., Бакулев А.Л., Белоусова Е.А., и соавт. Раннее назначение генно-инженерных биологических препаратов при иммуновоспалительных заболеваниях: возможности и перспективы. Позиция экспертов. Альманах клинической медицины. 2020; 48(6): 422 - 36. doi: 10.18786/2072-0505-2020-48-050.

81. Tay GS, Binion DG, Eastwood D, et al. Multivariate analysis suggests improved perioperative outcome in Crohn"s disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003; 34: 565 - 72.

82. Coward S, Kuenzig ME, Hazlewood G, et al. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn"s Disease: A Bayesian Network Meta-analysis. Inflamm Bowel Dis. 2017; 23(3): 461 - 472. doi: 10.1097/MIB.0000000000001023.

83. Rezaie A, Kuenzig ME, Benchimol EI, et al. Budesonide for induction of remission in Crohn"s disease. Cochrane Database Syst Rev. 2015; (6): CD000296. doi: 10.1002/14651858.CD000296.pub4.

84. Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn"s disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 617 - 29.

85. Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020; 14: 4 - 22.

86. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn"s disease. Cochrane Database Syst Rev. 2000; (2): CD000545. doi: 10.1002/14651858.CD000545.

87. Herfarth HH, Kappelman MD, Long MD, et al. Use of Methotrexate in the Treatment of Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016; 22: 224 - 33.

88. Chande N, Patton PH, Tsoulis DJet al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn"s disease. Cochrane Database Syst Rev. 2015; (10): CD000067.

89. Benchimol EI, Seow CH, Steinhart AH, et al. Traditional corticosteroids for induction of remission in Crohn"s disease. Cochrane Database Syst Rev 2008; 2: CD006792.

90. Khan KJ, Ullman TA, Ford AC, et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 661 - 73.

91. Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006; 24: 319 - 30.

92. Pearson DC, May GR, Fick GR, et al. Azathioprine for maintaining remission of Crohn"s disease. Cochrane Database Syst Rev. 2000(2): CD000067.

93. Hazlewood GS, Rezaie A, Borman M, et al. Comparative effectiveness of immunosuppressants and biologics for inducing and maintaining remission in Crohn"s disease: a network meta-analysis. Gastroenterology. 2015; 148(2): 344 - 54.

94. Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn"s disease. Aliment Pharmacol Ther. 2018; 48(4): 394 - 409.

95. Cholapranee A, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn"s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2017; 45(10): 1291 - 1302.

96. Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn"s Disease. Gastroenterology. 2020; 158(8): 2123 - 2138. doi: 10.1053/j.gastro.2020.01.047.

97. Johnson AM, Barsky M, Ahmed W, et al. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn"s Disease: Results From the SUCCESS Consortium. Am J Gastroenterol. 2023; 118(2): 317 - 328. doi: 10.14309/ajg.0000000000002047.

98. Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn"s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020; 51(10): 948 - 957. doi: 10.1111/apt.15706.

99. Biemans VBC, van der Woude CJ, Dijkstra G, et al. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn"s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020; 52(1): 123 - 134. doi: 10.1111/apt.15745

100. Loftus E.V., J, Lacerda A.P. et al. Upadacitinib Induction and Maintenance Therapy for Crohn"s Disease. Clinical Trial N Engl J Med. 2023; 388(21): 1966 - 1980. doi: 10.1056/NEJMoa2212728.

101. Sands BE, Irving PM, Hoops T, et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn"s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022; 399(10342): 2200 - 2211. doi: 10.1016/S0140-6736(22)00688-2. PMID: 35691323.

102. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn"s disease. Cochrane Database Syst Rev. 2009: CD000545.

103. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn"s disease. N Engl J Med. 2010; 362(15): 1383 - 95. doi: 10.1056/NEJMoa0904492.

104. O, Blumenstein I, Schulte-Bockholt A, et al. Combining infliximab and methotrexate in fistulizing Crohn"s disease resistant or intolerant to azathioprine. Aliment Pharmacol Ther. 2004; 19(3): 295 - 301.

105. Bressler B, Yarur A, Silverberg M et al. Vedolizumab and Anti-Tumour Necrosis Factor Real-World Outcomes in Inflammatory Bowel Disease Patients: Results from the EVOLVE Study. J Crohns Colitis. 2021; 15(10): 1694 - 1706. doi: 10.1093/ecco-jcc/jjab058.

106. Huang Z, Ba Y, Kamble P, et al. P267 Sequencing of anti-TNF agents and gut-selective anti-lymphocyte trafficking (GSALT) therapy in the treatment of Crohn's disease (CD). J Crohns Colitis. 2021; 15: 302 - 303. doi:10.1093/ecco-jcc/jjab076.392.

107. Zhuleku E, Antolin-Fontes B, Borsi A, et al. Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn"s Disease patients: A retrospective analysis using German claims data. Therap Adv Gastroenterol. 2022; 15: 17562848221130554. doi: 10.1177/17562848221130554.

108. Reinisch W, Gecse K, Halfvarson J et al Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn"s Disease. Inflamm Bowel Dis. 2021; 27(1): 106 - 122. doi: 10.1093/ibd/izaa078.

109. Roblin X, Williet N, Boschetti G, et al. Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial. Gut. 2020; 69(7): 1206 - 1212. doi: 10.1136/gutjnl-2019-319758.

110. Casanova MJ, Chaparro M, M, et al. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflamm Bowel Dis. 2020; 26(4): 606 - 616. doi: 10.1093/ibd/izz192.

111. Cordon JP, Arranz EM, Ramirez L, et al. What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF? J Crohns Colitis. 2020; 14 (Supplement_1): 554 - 554.

112. Ledder O, Turner D. Antibiotics in IBD: Still a Role in the Biological Era? Inflamm Bowel Dis. 2018; 24(8): 1676 - 1688.

113. Gionchetti P, Dignass A, Danese S, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn"s Disease 2016: Part 2: Surgical Management and Special Situations on behalf of ECCO. J Crohns Colitis. 2017; 11: 135 - 149.

114. Kawalec P, Mikrut A, N, et al. Meta-analysis/systematic review tumor necrosis (infliximab, adalimumab and certolizumab) in Crohn"s disease: systematic review and meta-analysis. Arch Med Sci. 2013; 9: 765 - 779.

115. Khorrami S, Ginard D, I, et al. Ustekinumab for the treatment of refractory Crohn"s disease the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016; 22: 1662 - 1669.

116. Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn"s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328 - 32.

117. Steinhart AH, Panaccione R, Targownik L, et al. Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn"s Disease: The Toronto Consensus. Inflamm Bowel Dis. 2019; 25(1): 1 - 13. doi: 10.1093/ibd/izy247.

118. Dewint P., Hansen B.E., Verhey E. et al. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn"s disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut.2014; 63(2): 292 - 9. doi: 10.1136/gutjnl-2013-304488.

119. Tandon P, Rhee GG, Schwartz D, et al. Strategies to Optimize Anti-tumor Necrosis Factor Therapy for Perianal Fistulizing Crohn"s Disease: A Systematic Review. Dig Dis Sci. 2019; 64(11): 3066 - 3077. doi: 10.1007/s10620-019-05635-1.

120. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn"s Disease. Gastroenterology. 2021; 160(7): 2496 - 2508. doi: 10.1053/j.gastro.2021.04.022.

121. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014; 8(6): 443 - 68. doi: 10.1016/j.crohns.2013.12.013.

122. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn"s disease. Gastroenterology 2004; 126: 402 - 13.

123. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Last accessed: September 2022.

124. IQVIA. The impact of biosimilar competition in Europe. 2021. Available at: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf. Last accessed: 17 October 2022.

125. Humphry N. The Rise of Anti-TNF Biosimilars: Guidelines, Real-World Evidence, and Challenges to Acceptance. EMJ Gastroenterol. 2022; 11: 2 - 10. doi:10.33590/emjgastroenterol/10106137.

126. Danese S, Fiorino G, Raine T, et al. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease - An Update. J Crohns Colitis. 2017; 11(1): 26 - 34. doi: 10.1093/ecco-jcc/jjw198.

127. Cohen HP, Blauvelt A, Rifkin RM, et al. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs. 2018; 78(4): 463 - 478. doi: 10.1007/s40265-018-0881-y.

128. Massimi D, Barberio B, Bertani L. et al. Switching from infliximab originator to SB2 biosimilar in inflammatory bowel diseases: a multicentric prospective real-life study. Ther Adv Gastroenterol. 2021; 14: 1 - 11.

129. Trystram N, Abitbol V, Tannoury J. et al. Outcomes after double switching from originator infliximab to biosimilar CT-P13 and biosimilar SB2 inpatients with inflammatory bowel disease: a 12-month prospective cohort study. Aliment Pharmacol Ther. 2021; 53: 887 - 99.

130. Mahmmod S, Schultheiss JPD, van Bodegraven AA. et al. Outcome of reverse switching from CT-P13 to originator infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021; 27: 1954 - 62.

131. Kaniewska M, Rosolowski M, Moniuzsko A. et al. Biosimilar infliximab versus originator in Crohn's disease and patients. Prz Gastroenterol. 2021; 16: 207 - 12.

132. Morris GA, McNikol M, Boyle B. et al. Increasing biosimilar utilization at a pediatric inflammatory bowel disease center and associated cost savings: show me the money. Inflamm Bowel Dis. 2022; 28: 531 - 8.

133. Barberio B. Cingolani L, Canova C. et al. A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. Ther Adv Gastroenterol. 2021; 14: 175 - 82.

134. Kurki P, Barry S., Bourges I. et al. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021; 81: 1881 - 96.

135. Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. J Crohns Colitis. 2013; 7(11): 853 - 67. doi: 10.1016/j.crohns.2013.01.014.

136. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: post-operative infectious complication risk in inflammatory bowel disease patients. Gastroenterology. 2003; 125: 320 - 327.

137. Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in vedolizumab-treated Crohn's disease patients undergoing major abdominal operations. Aliment Pharmacol Ther. 2018; 47: 573 - 580.

138. Kotze PG, Ghosh S, Bemelman WA, Panaccione R. Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. Intest Res. 2017; 15: 160 - 165.

139. Kotze PG, Saab MP, Saab B, et al. Tumor necrosis factor alpha inhibitors did not influence postoperative morbidity after elective surgical resections in Crohn's disease. Dig Dis Sci. 2017; 62: 456 - 464.

140. Law CCY, Narula A, Lightner AL, et al. Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease. J Crohns Colitis. 2018; 12: 538 - 545.

141. Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn's disease. J Crohns Colitis. 2018; 12: 402 - 407.

142. Novello M, Stocchi L, Holubar S, et al. Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis. Int J Colorectal Dis. 2019; 34: 451 - 457.

143. Ahmed Ali U, Martin ST, Rao AD, et al. Impact of preoperative immunosuppressive agents on postoperative outcomes in Crohn's disease. Dis Colon Rectum. 2014; 57: 663 - 674.

144. McKenna NP, Habermann EB, Glasgow AE, et al. Intra-abdominal sepsis after ileocolic resection in Crohn's disease: the role of combination immunosuppression. Dis Colon Rectum. 2018; 61: 1393 - 1402.

145. Podugu A, Tandon K, Castro FJ. Crohn's disease presenting as acute gastrointestinal hemorrhage. World J Gastroenterol. 2016; 22: 4073 - 4078.

146. Raphaeli T, Menon R. Current treatment of lower gastrointestinal hemorrhage. Clin Colon Rectal Surg. 2012; 25: 219 - 227.

147. Korzenik JR. Massive Lower Gastrointestinal Hemorrhage in Crohn"s Disease. Curr Treat Options Gastroenterol. 2000; 3(3): 211 - 216. doi: 10.1007/s11938-000-0024-9.

148. Liu RQ, Guo D, Qiao SH, et al. Comparison of primary anastomosis and staged surgery in emergency treatment of complicated Crohn"s disease. J Dig Dis. 2020; 21: 724 - 734.

149. Шелыгин Ю.А., Ачкасов С.И., Решетов И.В., и соавт. Консенсус по спорным вопросам хирургического лечения болезни Крона с применением Дельфийского метода. Колопроктология. 2023; 22 (2): 172 - 183 doi: 10.33878/2073-7556-2023-22-2-172-183.

150. Werbin N, Haddad R, Greenberg R, et al. Free perforation in Crohn"s disease. Isr Med Assoc J. 2003; 5(3): 175 - 7.

151. Papi C, Festa V, Fagnani C, et al. Evolution of clinical behaviour in Crohn"s disease: predictive factors of penetrating complications. Dig Liver Dis. 2005; 37(4): 247 - 53. doi: 10.1016/j.dld.2004.10.012.

152. Bemelman WA, Warusavitarne J, Sampietro GM, et al. ECCO-ESCP Consensus on Surgery for Crohn"s Disease. J Crohns Colitis. 2018; 12(1): 1 - 16. doi: 10.1093/ecco-jcc/jjx061.

153. Agha FP, Ghahremani GG, Panella JS, et al. Appendicitis as the initial manifestation of Crohn"s disease: radiologic features and prognosis. AJR Am J Roentgenol. 1987; 149(3): 515 - 8. doi: 10.2214/ajr.149.3.515.

154. Kaplan GG, Jackson T, Sands BE, et al. The risk of developing Crohn"s disease after an appendectomy: a meta-analysis. Am J Gastroenterol. 2008; 103(11): 2925 - 31. doi: 10.1111/j.1572-0241.2008.02118.x.

155. Quaresma AB, Miranda EF, Kotze PG. Management of ileocecal Crohn's disease during surgical treatment for acute appendicitis: a systematic review. Arquivos De Gastroenterologia. 2021; 4(58): 560 - 565.

156. Adamina M, Bonovas S, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn"s Disease: Surgical Treatment. J Crohns Colitis. 2020; 14(2): 155 - 168. doi: 10.1093/ecco-jcc/jjz187.

157. Clancy C, Boland T, Deasy J, et al. A Meta-analysis of Percutaneous Drainage Versus Surgery as the Initial Treatment of Crohn"s Disease-related Intra-abdominal Abscess. J Crohns Colitis. 2016; 10(2): 202 - 8. doi: 10.1093/ecco-jcc/jjv198.

158. L, F, Miranda-Bautista , et al. Safety and Efficacy of Treatment in Crohn"s Disease Patients with Abdominal Abscesses. Hepatogastroenterology. 2015; 62(139): 647 - 52.

159. Mascolino A, Scerrino G, Gullo R, et al. Large retroperitoneal abscess extended to the inferior right limb secondary to a perforated ileal Crohn"s disease: the importance of the multidisciplinary approach. G Chir. 2016; 37(1): 37 - 41. doi: 10.11138/gchir/2016.37.1.037.

160. Варданян А.В., Шапина М.В., Полетова А.В., и соавт. Факторы риска развития осложнений у пациентов, оперированных по поводу осложненной формы болезни Крона. Хирург. 2021; 3(4): 44 - 52.

161. He X, Lin X, Lian L, et al. Preoperative percutaneous drainage of spontaneous intra-abdominal abscess in patients with Crohn's disease: a meta-analysis. J Clin Gastroenterol. 2015; 9(49): 82 - 90.

162. Jawhari A, Kamm MA, Ong C, et al. Intra-abdominal and pelvic abscess in Crohn"s disease: results of noninvasive and surgical management. Br J Surg. 1998; 85(3): 367 - 71. doi: 10.1046/j.1365-2168.1998.00575.x.

163. Poggioli G, Stocchi L, Laureti S, et al. Conservative surgical management of terminal ileitis: side-to-side enterocolic anastomosis. Dis Colon Rectum. 1997; 40(2): 234 - 7. doi: 10.1007/BF02054994.

164. Melton GB, Fazio VW, Kiran RP, et al. Long-term outcomes with ileal pouch-anal anastomosis and Crohn"s disease: pouch retention and implications of delayed diagnosis. Ann Surg. 2008; 248(4): 608 - 16. doi: 10.1097/SLA.0b013e318187ed64.

165. Panes J, Bouhnik Y, Reinisch W, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013; 7(7): 556 - 85. doi: 10.1016/j.crohns.2013.02.020.

166. Rieder F, Zimmermann EM, Remzi FH, et al. Crohn's disease complicated by strictures: a systematic review. Gut. 2013; 62: 1072 - 1084.

167. Navaneethan U, Lourdusamy V, Njei B, et al. Endoscopic balloon dilation in the management of strictures in Crohn's disease: a systematic review and meta-analysis of non-randomized trials. Surg Endosc 2016; 30: 5434 - 5443.

168. Варданян А.В., Кашников В.Н., Болихов К.В., и соавт. Лапароскопическая илеостомия при болезни Крона. Колопроктология, 2011; 3(37): 20 - 23.

169. Воробьев Г.И., Болихов К.В., Варданян А.В. Место лапароскопической илеостомии в лечении болезни Крона толстой кишки (обзор литературы). Колопроктология, 2009; 3(29): 52 - 58.

170. Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn's disease: follow-up of a prospective randomized trial. Surgery. 2008; 144: 622 - 627.

171. Maartense S, Dunker MS, Slors JF, et al. Laparoscopic-assisted versus open ileocolic resection for Crohn's disease: a randomized trial. Ann Surg. 2006; 243: 143 - 150.

172. Sagar PM, Dozois RR, Wolff BG. Long-term results of ileal pouch-anal anastomosis in patients with Crohn"s disease. Dis Colon Rectum. 1996; 39(8): 893 - 8. doi: 10.1007/BF02053988.

173. Simillis C, Purkayastha S, Yamamoto T, et al. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn"s disease. Dis Colon Rectum. 2007; 50(10): 1674 - 87. doi: 10.1007/s10350-007-9011-8.

174. Stocchi L, Milsom JW, Fazio VW. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn"s disease: follow-up of a prospective randomized trial. Surgery. 2008; 144(4): 622 - 7. doi: 10.1016/j.surg.2008.06.016.

175. Tekkis PP, Purkayastha S, Lanitis S, et al. A comparison of segmental vs subtotal/total colectomy for colonic Crohn"s disease: a meta-analysis. Colorectal Dis. 2006; 8(2): 82 - 90. doi: 10.1111/j.1463-1318.2005.00903.x.

176. Teeuwen PH, Stommel MW, Bremers AJ, et al. Colectomy in patients with acute colitis: a systematic review. J Gastrointest Surg. 2009; 13: 676 - 686.

177. de Groof EJ, van der Meer JHM, Tanis PJ, et al. Persistent Mesorectal Inflammatory Activity is Associated With Complications After Proctectomy in Crohn"s Disease. J Crohns Colitis. 2019; 13(3): 285 - 293. doi: 10.1093/ecco-jcc/jjy131.

178. Mege D., Panis Y. Laparoscopic surgery for inflammatory bowel disease. Колопроктология. 2018; 2(64): 14 - 24.

179. Singh S, Ding NS, Mathis KL, et al. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn"s disease. Aliment Pharmacol Ther. 2015; 42(7): 783 - 92.

180. Щукина О.Б., Собко В.Ю., Горбачева Д.Ш., и соавт. Прогнозирование хирургического лечения болезни Крона. Колопроктология. 2015; 4(54): 33 - 40.

181. Tichansky D, Cagir B, Yoo E, et al. Strictureplasty for Crohn's disease: meta-analysis. Dis Colon Rectum. 2000; 43: 911 - 9.

182. Shivashankar R, Edakkanambeth Varayil J, Scott Harmsen W, et al. Outcomes of endoscopic therapy for luminal strictures in Crohn's disease. Inflamm Bowel Dis. 2018; 24: 1575 - 1581.

183. Wibmer AG, Kroesen AJ, J, et al. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn's disease-review of the literature. Int J Colorectal Dis. 2010; 25: 1149 - 1157.

184. Reese GE, Purkayastha S, Tilney HS, et al. Strictureplasty vs. resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. 2007; 9: 686 - 94.

185. Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn's disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007; 50: 1968 - 86.

186. Dietz DW, Laureti S, Strong SA, et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn"s disease. J Am Coll Surg. 2001; 192(3): 330 - 7. doi: 10.1016/s1072-7515(01)00775-x.

187. Шелыгин Ю.А., Халиф И.Л, Кашников В.Н., и соавт. Илеостомия в лечении болезни Крона толстой кишки с перианальными поражениями. Колопроктология. 2011; 3(37): 33.

188. Шапина М.В., Халиф И.Л., Нанаева Б.А. Применение цертолизумаба пэгола при болезни Крона. Обзор литературы. Колопроктология. 2016; 3(57): 102 - 108.

189. van Dongen LM, Lubbers EJC. Perianal fistulas in patients with Crohn's disease. Arch Surg. 1986; 121: 1187 - 90.

190. Yamamoto T, Allan RN, Keighley MR. Effect of fecal diversion alone on perianal Crohn's disease. World J Surg. 2000; 24: 1258 - 62.

191. El-Gazzaz G, Hull T, Church JM. Biological immunomodulators improve the healing rate in surgically treated perianal Crohn"s fistulas. Colorectal Dis. 2012; 14(10): 1217 - 23. DOI:10.1111/j.1463-1318.2012.02944.x.

192. Thornton M, Solomon MJ. Long-term indwelling seton for complex anal fistulas in Crohn's disease. Dis Colon Rectum. 2005; 48(3): 459 - 63.

193. Stellingwerf ME, van Praag EM, Tozer PJ, et al. Systematic review and meta-analysis of endorectal advancement flap and ligation of the intersphincteric fistula tract for cryptoglandular and Crohn"s high perianal fistulas. BJS Open. 2019; 3: 231 - 241. DOI: 10.1002/bjs5.50129.

194. Adegbola SO, Sahnan K, Tozer PJ, et al. Symptom Amelioration in Crohn"s Perianal Fistulas Using Video-Assisted Anal Fistula Treatment (VAAFT). J Crohns Colitis. 2018; 12: 1067 - 1072. DOI: 10.1093/ecco-jcc/jjy071.

195. Cao D, Li W, Ji Y, et al. Efficacy and safety of FiLaC^TM for perianal fistulizing Crohn"s disease: a systematic review and meta-analysis. Tech Coloproctol. 2022; 26(10): 775 - 781. DOI: 10.1007/s10151-022-02682-1.

196. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn"s disease. Gastroenterology 1990; 99: 956 - 63.

197. Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004; 126(6): 1504 - 17.

198. Полетова А.В., Шапина М.В., Халиф И.Л., и соавт. Эффективность послеоперационной противорецидивной терапии Адалимумабом и азатиоприном при болезни Крона. Колопроктолгия. 2018; 2(64): 73 - 77.

199. Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn"s disease: a meta-analysis. Am J Gastroenterol. 2009; 104(8): 2089 - 96. doi: 10.1038/ajg.2009.301.

200. Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009; 136: 441 - 50.

201. Malchow H, Ewe K, Brandes JW, et al. European co-operative Crohn"s disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249 - 66.

202. Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn"s disease: a randomized controlled trial. Am J Gastroenterol. 2013; 108(11): 1731 - 42. doi: 10.1038/ajg.2013.287.

203. Yamada A, Komaki Y, Patel N, et al. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn"s Disease. Inflamm Bowel Dis. 2018; 24(3): 502 - 509.

204. Lu TX, Cohen RD. Maneuvering Clinical Pathways for Crohn"s Disease. Curr Gastroenterol Rep. 2019; 21(5): 20.

205. Bhattacharya A, Shen B, Regueiro M. Endoscopy in Postoperative Patients with Crohn"s Disease or Ulcerative Colitis. Does It Translate to Better Outcomes? Gastrointest Endosc Clin N Am. 2019; 29(3): 487 - 514. doi: 10.1016/j.giec.2019.02.013.

206. Chu KF, Moran CJ, Wu K, et al. Performance of Surveillance MR Enterography (MRE) in Asymptomatic Children and Adolescents With Crohn"s Disease. J Magn Reson Imaging. 2019; 50(6): 1955 - 1963. doi: 10.1002/jmri.26811.

207. Deepak P, Axelrad JE, Ananthakrishnan AN. The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. Gastrointest Endosc Clin N Am. 2019; 29(3): 447 - 470. doi: 10.1016/j.giec.2019.02.006.

208. Brand EC, Elias SG, Minderhoud IM, et al. Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn"s Disease. Clin Gastroenterol Hepatol. 2020; 18(8): 1704 - 1718. doi: 10.1016/j.cgh.2019.12.014.

209. Terdiman JP. Prevention of postoperative recurrence in Crohn"s disease. Clin Gastroenterol Hepatol. 2008; 6(6): 616 - 20. doi: 10.1016/j.cgh.2007.08.020.

210. Papamichael K, Archavlis E, Lariou C, et al. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn"s disease: a prospective, two-year, single center, pilot study. J Crohns Colitis. 2012; 6(9): 924 - 31. doi: 10.1016/j.crohns.2012.02.012.

211. Халиф И.Л., Варданян А.В., Шапина М.В., и соавт. Противорецидивная терапия болезни Крона в послеоперационном периоде (обзор литературы). Колопроктология. 2017; 3(61): 63 - 70.

212. Loly C, Belaiche J, Louis E. Predictors of severe Crohn"s disease. Scand J Gastroenterol 2008; 43: 948 - 54.

213. Министерство здравоохранения Российской федерации. Клинические рекомендации "Язвенный колит". Available: https://cr.minzdrav.gov.ru/schema/193_1

214. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., и соавт. Современные возможности улучшения функционального состояния запирательного аппарата у пациентов с наличием превентивных кишечных стом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; 5: 77 - 83.

215. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., и соавт. Современные возможности улучшения функционального состояния запирательного аппарата у пациентов с наличием превентивных кишечных стом. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2015; 5: 77 - 83.

216. Фоменко О.Ю., Ачкасов С.И., Титов А.Ю., и соавт. Роль аноректальной манометрии, БОС-терапии и тибиальной нейромодуляции в диагностике и консервативном лечении анальной инконтиненции у пожилых. Клиническая геронтология. 2015; 5 - 6: 16 - 20.

217. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412 - 22.

218. Olivera P.A., Zuily S., Kotze P.G., et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Gastroenterology & Hepatology. 2021; 18: 858 - 873.

219. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО) Флебология, 2015; 4(22).

220. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010; 8(11): 2450 - 7. doi: 10.1111/j.1538-7836.2010.04044.x.

221. Caprini J.A. Risk assessment as a guide to thrombosis prophylaxis. Curr Opin Pulm Med. 2010; 16(5): 448 - 52. doi: 10.1097/MCP.0b013e32833c3d3e.

222. Ishige T, Shimizu T, Watanabe K, et al. Expert consensus on vaccination in patients with inflammatory bowel disease in Japan. J Gastroenterol. 2023; 58(2): 135 - 157. doi: 10.1007/s00535-022-01953-w.

223. Kucharzik T, Ellul P, Greuter T, et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis. 2021; 15(6): 879 - 913. doi: 10.1093/ecco-jcc/jjab052.

224. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58(3): 309 - 18.

225. Вакцины и иммунопрофилактика в современном мире: руководство для врачей/под ред. Л.С. Намазовой-Барановой, Н.И. Брико, И.В. Фельдблюм. - М.: ПедиатрЪ, 2021. - 646 с.

226. Приказ МЗ РФ от 06.12.2021 N 1122н "Об утверждении национального календаря профилактических прививок и календаря профилактических прививок по эпидемическим показаниям", Методические указания МУ 3.3.1.1095-02. Медицинские противопоказания к проведению профилактических прививок препаратами национального календаря прививок.

227. Санитарные правила и нормы СанПиН 3.3686-21 "Санитарно-эпидемиологические требования по профилактике инфекционных болезней" Постановление главного санитарного врача от 28 января 2021 г. N 4.

228. Стратегия развития иммунопрофилактики инфекционных заболеваний на период до 2035 года, утверждена распоряжением Правительства Российской Федерации от 18 сентября 2020 г. N 2390-р.

229. Временные методические рекомендации "Порядок проведения вакцинации против новой коронавирусной инфекции (COVID-19)" Москва 2022 г. Available: https://static-0.minzdrav.gov.ru/system/attachments/attaches/system/attachments/attaches/000/060/087/original/Методические_рекомендации_02062022_%282%29.pdf?1655803717

230. Jena A, James D, Singh AK, et al. Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2022; 20(7): 1456 - 1479.

231. Kubas A, Malecka-Wojciesko E. COVID-19 Vaccination in Inflammatory Bowel Disease (IBD). J Clin Med. 2022; 11(9): 2676. doi: 10.3390/jcm11092676.

232. Временные методические рекомендации: "Болезни органов пищеварения в условиях пандемии новой коронавирусной инфекции (COVID-19)". Версия 2. Консенсус экспертов Межрегиональной общественной организации "Общество гастроэнтерологов и гепатологов "Северо-Запад", Российского общества профилактики неинфекционных заболеваний и Профильной комиссии по терапии и общей врачебной практике Минздрава России. Профилактическая медицина. 2021; 5(24): 4 - 41.

233. D'Haens G, J, Louis E, et al. Upadacitinib Was Efficacious and Well-tolerated Over 30 Months in Patients With Crohn's Disease in the CELEST Extension Study. Clinical Gastroenterology and Hepatology 2022; 20: 2337 - 2346.

234. Stavem K. Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review. J Mark Access Health Policy. 2021; 9(1): 1964792. Published online 2021Aug 20. DOI: 10.1080/20016689.2021.1964792

235. Князев О.В., Звяглова М.Ю., Каграманова А.В. и соавт. Потеря ответа и частота нежелательных явлений у пациентов с язвенным колитом и болезнью Крона при переходе с оригинального препарата инфликсимаб на его биосимиляры. Терапевтический архив. 2021; 93 (2): 150 - 157. DOI: 10.26442/00403660.2021.02.200624.

236. Madanchi M, Fagagnini S, Fournier N et al.Swiss IBD Cohort Study Group, The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort, Inflammatory Bowel Diseases, Volume 24, Issue 8, August 2018, Pages 1768 - 1779

237. Issa M, Vikayapal A, Gracham MB et al. Impact of Clostridium difficile in inflammatory bowel disease patients. Clin Gastroenterol Hepatol. 2007; 5: 345 - 351.

238. Rodeman JF, Dubberke ER, Reske KA et al. Incidence of Clostridium difficile in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 339 - 344.

239. Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1432 - 42.

240. Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol. 1999 Jul 15; 58(2): 363 - 8.

241. Mager DE, Lin SX, Blum RA, et al. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003 Nov; 43(11): 1216 - 27.

242. Janier M, Hegyi V, Dupin N,et al. 2014 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol. 2014 Dec; 28(12): 1581 - 93.

243. van der Have M, Belderbos TD, Fidder HH, Dutch Initiative on Crohn and Colitis (ICC). Screening prior to biological therapy in Crohn"s disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study. Dig Liver Dis. 2014 Oct; 46(10): 881 - 6.

244. Velayos FS, Sandborn WJ. Use of azathioprine and 6MP in postoperative Crohn"s: changing natural history or just along for the ride? Am J Gastroenterol. 2009 Aug; 104(8): 2097 - 9.

245. De Cruz P, Kamm MA, Hamilton AL et al. Efficacy of thiopurines and adalimumab in preventing Crohn"s disease recurrence in high-risk patients - a POCER study analysis. Aliment Pharmacol Ther. 2015 Oct; 42(7): 867 - 79.

246. Vader JP, Froehlich F, Juillerat P, Burnand B, Felley C, Gonvers JJ, Mottet C, Pittet V, Dubois RW, Wietlisbach V, Michetti P. Appropriate treatment for Crohn"s disease: methodology and summary results of a multidisciplinary international expert panel approach--EPACT. Digestion. 2006; 73(4): 237 - 48

247. Kappelman MD, Palmer L, Boyle BM, et al. Quality of care in inflammatory bowel disease: a review and discussion. Inflamm Bowel Dis. 2010 Jan; 16(1): 125 - 33.

248. Fiorino G, Allocca M, Chaparro M, et al.'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review, Journal of Crohn"s and Colitis. 2019 Jan, 13(1): 127 - 137.

249. Tulchinsky H. et al. Comprehensive pouch clinic concept for follow-up of patients after ileal pouch anal anastomosis: report of 3 years" experience in a tertiary referral center.Inflamm Bowel Dis, 2008. 14(8): 1125 - 32.

250. Calvet X, J, Alfaro N, et al. Delphi consensus statement: Quality Indicators for Inflammatory Bowel Disease Comprehensive Care Units. J Crohns Colitis. 2014 Mar; 8(3): 240 - 51.

251. Meima-van Praag EM, Buskens CJ, Hompes R, et al. Surgical management of Crohn"s disease: a state of the art review. Int J Colorectal Dis. 2021 Jun; 36(6): 1133 - 1145.

252. Cosnes J, Bourrier A, Laharie D, et al. Groupe d"Etude des Affections Inflammatoires du Tube Digestif (GETAID). Early administration of azathioprine vs conventional management of Crohn"s Disease: a randomized controlled trial. Gastroenterology. 2013 Oct; 145(4): 758 - 65 .e2; quiz e14-5.

253. Rayer, C., Nachury, M., Bourreille, A. et al. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study. BMC Gastroenterol 22, 498 (2022)

254. Sharip MT, Nishad N, Pillay L, Goordoyel N, Goerge S, Subramanian S. Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn"s Disease: A Review of Comparative Effectiveness Studies. J Clin Med. 2024 Apr 10; 13(8): 2187.

255. Barberio B, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn"s disease: systematic review and network meta-analysis. Gut. 2023 Feb; 72(2): 264 - 274.

256. Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn"s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 Dec; 6(12): 1002 - 1014.